Our Pipeline

We are progressing a diverse small molecule pipeline to meet the unmet medical needs to patients across most severe neurological and lysosomal storage disorders as well as most devastating cancers

Indication	Hit Identification	Lead Optimisation	Preclinical Toxicology	Phase 1 Clinical Trial	Phase 2 Clinical Trial
Cognition in Schizophrenia
Anxiety Disorders
Major Depressive Disorder
Postpartum Depression
Schizophrenia
Chronic Pain
Krabbe Disease
Depression
Motor Neuron Disease
Undisclosed Lysosomal Target
Acute Myeloid Leukaemia
Colon Cancer